Sarah Sammons, MD, Duke Cancer Institute

Targeting the PI3K Pathway in HR+/HER2- MBC

November 15th 2021

The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.

Dr. Sammons on the Clinical Implications of DESTINY-Breast03 in HER2+ Breast Cancer

November 9th 2021

Sarah Sammons, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

CDK4/6 Treatment Selection for HR+/HER2- MBC

November 8th 2021

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities

November 1st 2021

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

HR+/HER2- MBC: CDK4/6 Inhibitors + ET as Frontline Therapy

November 1st 2021

Dr. Sarah Sammons highlights various first-line treatment approaches that combine CDK4/6 inhibitors with endocrine therapy as treatment for HR+/HER2- metastatic breast cancer.

HR+/HER2- MBC: Updated OS Data From MONALEESA-2

October 18th 2021

Reactions to new overall survival results from the MONALEESA-2 study in patients with HR+/HER2- advanced breast cancer in the first-line setting.

Frontline Treatment Approaches for HR+/HER2- MBC

October 18th 2021

A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.

HR+ MBC: Prognostic Factors and Treatment Planning

October 11th 2021

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Identifying PIK3CA Mutations in HR+ HER2- MBC

October 11th 2021

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.

Dr. Sammons on Research Efforts Examining Lasofoxifene in ESR1-Mutant Breast Cancer

December 17th 2020

Sarah Sammons, MD, discusses clinical trials examining lasofoxifene in patients with ESR1-mutant breast cancer.

Precision Medicine in Metastatic Triple Negative Breast Cancer

September 16th 2020

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

September 16th 2020

Metastatic HER2+ Breast Cancer

September 16th 2020

Metastatic HR+ Breast Cancer

September 16th 2020